|
|
|
|
A phase III doulbe-blind placebo-controlled clinical trail demonstrated that interferon beta-la(IFNB-1a)(Avonex,Biogen)significantly delayed progression of disability in relapsing MS patients.The objective of this study was to examine the magnitude of benefit on EDSS and its clinical significance.The primary clinical outcome for the IFNB-1a clinical trail underestimated clinical benefits of treatment.Results in this report demonstrate that IFNB-1a treatment is associated with robust,clinically important beneficial effects on disability progression in relapsing MS patients. |
|